Megan Hyland1, Richard A Rudick. 1. Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes standard and evolving outcome measures in multiple sclerosis (MS) clinical trials. RECENT FINDINGS: Progress in the development of MS treatments has led to an increasing number of clinical trials and a need for sensitive, timely, and clinically relevant outcome measures. Relapse rate and the Expanded Disability Status Scale remain the standard clinical outcome measures, but the MS Functional Composite continues to gain additional validation as a meaningful outcome measure. The uncertain relationship between MRI outcome measures and clinical disability has been a persistent challenge in MS clinical trials, but there is increasing evidence supporting a correlation between MRI changes and disability in relapsing-remitting MS patients. Additionally, new imaging techniques are being developed to further increase the sensitivity of MRI as a tool in MS clinical trials. Optical coherence tomography is another outcome measure gaining influence in clinical trials. Some of the greatest challenges remain in the subset of primary progressive MS clinical trials in which brain atrophy appears to be the most promising imaging outcome measure, but the optimal clinical measures and study durations are still uncertain. SUMMARY: Progress in MS clinical trials requires critical evaluation of existing and future outcome measures and their relationships to one another.
PURPOSE OF REVIEW: This review summarizes standard and evolving outcome measures in multiple sclerosis (MS) clinical trials. RECENT FINDINGS: Progress in the development of MS treatments has led to an increasing number of clinical trials and a need for sensitive, timely, and clinically relevant outcome measures. Relapse rate and the Expanded Disability Status Scale remain the standard clinical outcome measures, but the MS Functional Composite continues to gain additional validation as a meaningful outcome measure. The uncertain relationship between MRI outcome measures and clinical disability has been a persistent challenge in MS clinical trials, but there is increasing evidence supporting a correlation between MRI changes and disability in relapsing-remitting MS patients. Additionally, new imaging techniques are being developed to further increase the sensitivity of MRI as a tool in MS clinical trials. Optical coherence tomography is another outcome measure gaining influence in clinical trials. Some of the greatest challenges remain in the subset of primary progressive MS clinical trials in which brain atrophy appears to be the most promising imaging outcome measure, but the optimal clinical measures and study durations are still uncertain. SUMMARY: Progress in MS clinical trials requires critical evaluation of existing and future outcome measures and their relationships to one another.
Authors: Guillaume Mathey; Guillaume Pisché; Marc Soudant; Sophie Pittion-Vouyovitch; Francis Guillemin; Marc Debouverie; Jonathan Epstein Journal: J Neurol Date: 2021-03-31 Impact factor: 4.849
Authors: Claire M Rice; David I Marks; Yoav Ben-Shlomo; Nikos Evangelou; Paul S Morgan; Chris Metcalfe; Peter Walsh; Nick M Kane; Martin G Guttridge; Gail Miflin; Stuart Blackmore; Pamela Sarkar; Juliana Redondo; Denise Owen; David A Cottrell; Alastair Wilkins; Neil J Scolding Journal: Trials Date: 2015-10-14 Impact factor: 2.279
Authors: Ahmed Abdelhak; Andre Huss; Alexander Stahmann; Makbule Senel; Markus Krumbholz; Markus C Kowarik; Joachim Havla; Tania Kümpfel; Ingo Kleiter; Isabella Wüstinger; Uwe K Zettl; Margit Schwartz; Romy Roesler; Tim Friede; Albert C Ludolph; Ulf Ziemann; Hayrettin Tumani Journal: Contemp Clin Trials Commun Date: 2020-05-19
Authors: Fahmy Aboulenein-Djamshidian; Martin Krššák; Nermin Serbecic; Helmut Rauschka; Sven Beutelspacher; Ivica Just Kukurová; Ladislav Valkovič; Adnan Khan; Daniela Prayer; Wolfgang Kristoferitsch Journal: PLoS One Date: 2015-11-13 Impact factor: 3.240